TITLE

Persistence of Botulinum Toxin in Patients' Serum: Alaska, 1959-2007

AUTHOR(S)
Fagan, Ryan P.; McLaughlin, Joseph B.; Middaugh, John P.
PUB. DATE
April 2009
SOURCE
Journal of Infectious Diseases;4/1/2009, Vol. 199 Issue 7, p1029
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Persistence of circulating toxin in patients with foodborne botulism is not well characterized. Recommendations for administration of botulinum antitoxin are ambiguous for patients with late-presenting disease, such as a Florida woman with toxin-positive serum 12 days after toxin ingestion. We reviewed Alaska records of foodborne outbreaks of botulism that occurred during 1959-2007 to examine the period after ingestion during which toxin was detected. Of 64 cases with toxin-positive serum, toxin was detected up to 11 days after ingestion. The findings from Alaska and Florida support administration of antitoxin up to 12 days after toxin ingestion but do not indicate when circulating toxin should no longer be present.
ACCESSION #
37016558

 

Related Articles

  • Botox has long duration of action for Tx of axillary hyperhidrosis. Kuznar, Wayne // Dermatology Times;May2004, Vol. 25 Issue 5, p94 

    Examines the effect of intradermal botulinum toxin type A for the treatment of primary axillary hyperhidrosis in a study in the U.S. Efficacy of the botulinum toxin type A; Patients enrolled in the study; Use of botulinum toxin in various forms of hyperhidrosis.

  • Botulinum Toxin Type A for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double-Blind, Placebo-Controlled Trial. Silberstein, Stephen D.; Stark, Stuart R.; Lucas, Sylvia M.; Christie, Suzanne N.; DeGryse, Ronald E.; Turkel, Catherine C. // Mayo Clinic Proceedings;Sep2005, Vol. 80 Issue 9, p1126 

    OBJECTIVES: To identify a treatment-responsive population for botulinum toxin type A (BoNTA) and to evaluate the safety and efficacy of 3 different doses of BoNTA as prophylactic treatment of chronic daily headache (CDH). PATIENTS AND METHODS: A randomized, double-blind, placebo-controlled study...

  • Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Ã… resolution. Hanson, Michael A.; Stevens, Raymond C. // Nature Structural Biology;Aug2000, Vol. 7 Issue 8, p687 

    Botulinum neurotoxin serotype B is a zinc protease that disrupts neurotransmitter release by cleaving synaptobrevin-II (Sb2), one of three SNARE proteins involved in neuronal synaptic vesicle fusion. The three-dimensional crystal structure of the apo botulinum neurotoxin serotype B catalytic...

  • Uses of botulinum toxin injection in medicine today. Munchau, A.; Bhatia, K. P. // BMJ: British Medical Journal (International Edition);01/15/2000, Vol. 320 Issue 7228, p161 

    Discusses the uses of botulinum toxin injection in modern medicine. Mode of action; Rationale for treatment with botulinum neurotoxin; Side effects of the toxin; Indications for treatment.

  • The many faces of botox. Cohen, Sharon; Kallen, Ben // Shape;Jul2004, Vol. 23 Issue 11, p93 

    Reports on various uses of botulinum toxin.

  • Editors' Response to Johnson. Hooper, David C.; Hirsch, Martin S. // Journal of Infectious Diseases;Sep2014, Vol. 210 Issue 6, p993 

    A response from the editor related to articles regarding the purported new botulinum neurotoxin serotype H published in a 2014 issue is presented.

  • Moving across membranes. Neale, Elaine A. // Nature Structural Biology;Jan2003, Vol. 10 Issue 1, p2 

    Discusses results from studies on botulinum neurotoxin which suggested that the toxin heavy chain function as both a channel and a chaperone for translocation of the catalytically active light chain. Agents that blocked toxin-induced inhibition of neurotransmitter release; Protein toxins that...

  • Response to Rupp and Segelke. Stevens, Raymond; Hanson, Michael // Nature Structural Biology;Aug2001, Vol. 8 Issue 8, p664 

    Responds to a commentary on an article which reported the cocrystal structure of the botulinum neurotoxin B light chain in complex with a 38-residue target peptide of synaptobrevin II. Clarification on peptide estimation; Observation on the outcome of translocation domain separation.

  • Validity of Botulinum Neurotoxin Serotype H. Johnson, Eric A. // Journal of Infectious Diseases;Sep2014, Vol. 210 Issue 6, p992 

    A letter to the editor is presented in response to several articles and commentaries regarding the purported new botulinum neurotoxin serotype H published in 2014 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics